BioSpace News Archive

Oxford Finance LLC announced the closing of a $20 million senior secured term loan to AliveCor, Inc., a privately held company focused on using artificial intelligence to improve cardiac care.

Citing unaffordable costs of common, essential drugs such as insulin, the Association of American Physicians and Surgeons (AAPS) provided testimony for the Jan 29 Senate Finance Committee hearing on high drug prices.

The FDA’s focus on both safety and innovation stems from our historic mission to protect and promote public health—to assure that medical devices on the U.S. market are high-quality, safe and effective and to facilitate innovation and assure that patients and providers have timely and continued access to these high-quality, safe and effective devices.

Optibrium™, a developer of software for drug discovery, today announced the appointment of Clare Devlin as Financial Director.

Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) welcomes an editorial published in the leading peer-reviewed journal Anesthesiology, accompanying the print publication of results from its positive Phase 3 clinical trial of BARHEMSYS™ (intravenous amisulpride) as rescue treatment of established post-operative nausea & vomiting (PONV).

This weekend, El Centro Hispano in Jonesboro and Arkansas State University are partnering with the National Alliance for Hispanic Health to host the National Institutes of Health’s All of Us Journey, a traveling, hands-on exhibit that raises awareness about the All of Us Research Program

Wolters Kluwer Legal & Regulatory U.S. today announced that registration is open for its 2019 three-part webinar series to help healthcare professionals understand the complex questions and legal issues surrounding consent to treatment.

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the closing of its previously announced public offering of 4,207,317 ordinary shares, including 548,780 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares.

Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the fourth quarter and full-year 2018 after the close of market on Monday, February 25, 2019.

CardioChek® Plus analyzer to be rolled out in more than 2000 Kroger Health clinics and pharmacies across the country